利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

41 条记录 (耗时 0.043 秒)

    Anti-allergic bis phenylene compositions and uses
    3.
    发明授权
    Anti-allergic bis phenylene compositions and uses 失效
    抗过敏双亚苯基组合物及用途

    公开(公告)号：US4156012A

    公开(公告)日：1979-05-22

    申请号：US841861

    申请日：1977-10-06

    申请人： Charles M. Hall ,  John B. Wright

    发明人： Charles M. Hall ,  John B. Wright

    IPC分类号： A61K31/24 ,  A61K31/275 ,  C07C255/58

    CPC分类号： A61K31/275 ,  A61K31/24 ,  C07C255/58

    摘要： A method of treating mammals for allergy and anaphylactic reactions of a reagin or non-reagin mediated nature which comprises administering prophylactically to said mammal an anti-allergy or anaphylactic reaction effective amount of a compound of the formula ##STR1## Novel compositions are also claimed.

    摘要翻译： 一种治疗哺乳动物用于过敏反应和过敏性反应的方法，其包括对所述哺乳动物预防性施用抗过敏或过敏反应有效量的下式化合物新颖的组合物。

    Compounds, compositions and methods of use
    5.
    发明授权
    Compounds, compositions and methods of use 失效
    化合物，组合物和使用方法

    公开(公告)号：US4067995A

    公开(公告)日：1978-01-10

    申请号：US635808

    申请日：1975-11-28

    申请人： John B. Wright ,  Anthony A. Sinkula

    发明人： John B. Wright ,  Anthony A. Sinkula

    IPC分类号： A61K31/22 ,  A61K31/00 ,  A61K31/275 ,  A61P37/08 ,  C07C67/00 ,  C07C253/00 ,  C07C255/60 ,  C07D205/04 ,  C07D295/08 ,  C07C121/78

    CPC分类号： C07D261/08

    摘要： It has now been discovered that novel compounds of FIG. 1 ##STR1## are useful in the prophylactic treatment of sensitized humans and animals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature. Additionally, the compounds are intermediates to the diacid or di salts which have utility in the same area as the esters. The compounds are formulated with pharmaceutical carriers for oral, parenteral, inhalation, or rectal means of administration.

    摘要翻译： 现在已经发现，图1的新化合物 1 可用于预防性治疗致敏人和动物的变态反应和所有过敏反应的反应素或非试剂介导性质。 另外，化合物是二酸或二盐的中间体，其在与酯相同的区域中具有效用。 化合物与用于口服，肠胃外，吸入或直肠给药方式的药物载体一起配制。

    3,3'-(2,6-PYRIDINEDIYL-5-ISOXAZOLE CARBOXYLIC ACIDS, SALTS, AND ESTERS, COMPOSITIONS AND METHODS OF USE THEREOF
    6.
    发明授权
    3,3'-(2,6-PYRIDINEDIYL-5-ISOXAZOLE CARBOXYLIC ACIDS, SALTS, AND ESTERS, COMPOSITIONS AND METHODS OF USE THEREOF 失效
    3,3 {40 - （2,6-吡啶二基-5-异辛唑羧酸，盐和酯，组合物及其使用方法

    公开(公告)号：US4066769A

    公开(公告)日：1978-01-03

    申请号：US753719

    申请日：1976-12-23

    申请人： John B. Wright

    发明人： John B. Wright

    IPC分类号： C07D213/78 ,  C07D413/14

    CPC分类号： C07D213/78

    摘要： Novel compounds of the formula ##STR1## wherein X is hydrogen, alkyl of one to six carbon atoms, inclusive, alkoxy of one to six atoms, inclusive, phenyl, cyano, nitro, trifluoromethyl, fluoro, chloro or bromo;R is hydrogen, alkyl of one to eight carbon atoms, inclusive, and a physiologically acceptable metal or amine cation and novel compositions wherein R is hydrogen or a physiologically acceptable metal or amine cation are used for prophylactically treating allergic disorders such as asthma.BRIEF SUMMARY OF THE INVENTIONIt has now been discovered that novel compounds of Formula I are useful in the prophylactic treatment of sensitized humans and animals for allergy and anaphylactic reactions of a reagin or non-reagin mediated nature. The compounds are formulated with pharmaceutical carriers for oral, parenteral, inhalation or rectal means of administration.DETAILED DESCRIPTION OF THE INVENTION ##STR2## wherein X is hydrogen, alkyl of one to six carbon atoms, inclusive, alkoxy of one to six carbon atoms, inclusive, phenyl, cyano, nitro, trifluoromethyl, fluoro, chloro or bromo;R is hydrogen, alkyl of one to eight carbon atoms, inclusive, and a physiologically acceptable metal or amine cation.Another group of compounds, hereafter referred to as Group B, are those compounds of Group A wherein R is hydrogen, alkyl of one to six carbon atoms, inclusive, or a physiologically acceptable metal or amine cation; X is hydrogen, alkyl of one to four carbon atoms, inclusive, alkoxy of one to four carbon atoms, inclusive, phenyl, cyano, nitro, trifluoromethyl, fluoro, chloro and bromo.A further group of compounds, hereafter referred to as Group C, are those compounds of Group B wherein R is hydrogen, alkyl of one to three carbon atoms, inclusive, or a physiologically acceptable metal or amine cation; X is hydrogen, alkyl of one to three carbon atoms, inclusive, alkoxy of one to three carbon atoms, inclusive, phenyl, cyano, trifluoromethyl, fluoro, chloro or bromo.Another group of compounds, hereafter referred to as Group D, are those compounds of Group C wherein X is hydrogen, alkyl of one to three carbon atoms, inclusive, alkoxy of one to three carbon atoms, inclusive, cyano thrifluoromethyl, fluoro and chloro.A further group of compounds are those compounds of Group D wherein X is at the four position.The tris(hydroxymethyl)aminomethane salt of the compound of the formula wherein X is hydrogen is preferred.As employed in the above disclosure and throughout the specification and claims, the phrase "alkyl of one to eight carbon atoms, inclusive" includes methyl, ethyl, propyl, butyl pentyl, hexyl, heptyl, octyl and isomers thereof. Illustrative examples of isomers are isopropyl, tert.butyl, neopentyl, 2,2-dimethylbutyl, 2-methylhexyl, and 2,2,4-trimethylphentyl. Alkyl of a smaller number of carbon atoms has a similar scoping.The phrase "physiologically acceptable amine salt" refers to amines which are accepted by mammals in an essentially non-toxic manner when administered to mammals in conjunction with the acid moiety of the invention. Illustrative of the amines are those derived from primary, secondary or tertiary amines. Examples of suitable amines are methylamine, dimethylamine, triethylamine, ethylamine, dibutylamine, triisopropylamine, N-methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, .alpha.-phenylethylamine, .beta.-phenylethylamine, ethylenediamine, diethylenetriamine, adamantylamines, and like aliphatic, cycloaliphatic, and araliphatic amines containing up to and including about eighteen carbon atoms, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereof, e.g., 1-methylpiperidine, 4-ethylmorpholine, 1-isopropylpyrrolidine, 2-methylpyrrolidine, 1,4-dimethylpiperazine, 2-methylpiperidine, and the like, as well as amines containing water-solubilizing or hydrophilic groups, e.g., mono-, di-, and triethanolamine, ethyldiethanolamine, N-butylethanolamine, 2-amino-1-butanol, 2-amino-1-ethyl-1,3-propanediol, 2-amino-2-methyl-1-propanol, tris(hydroxymethyl)aminomethane, N-phenylethanolamine, N-(p-tert-amylphenyl)diethanolamine, galactamine, N-methylglucamine, N-methylglucosamine, ephedrine, phenylephrine, epinephrine, procaine, and the like. Also included within the amine scope are quaternary amines such as ammonium, tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, phenyltriethylammonium, and the like.The term "physiologically acceptable metal" includes alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, and other acceptable metals such as aluminum.The compounds of the invention can be prepared by methods known in the art.With respect to the 5-isoxazole carboxylates, acids and salts thereof, the appropriately substituted pyridine dialdehyde (II) is a suitable starting material. These compounds are reacted with an acid addition salt of hydroxylamine, for example, hydroxylamine hydrochloride (III) under standard conditions to form a dioxime (IV). The dioxime is then reacted with a halogen such as chlorine or bromine in an inert organic solvent at a low temperature to form the .alpha.,.alpha.-dihalopyridyl-dioxime (V). The product of Formula V is then reacted with an alkyl propiolate (VI) in organic solvent containing an organic base to form the 5-isoxazolecarboxylate. ##STR3##The esters of Formula VII are readily transesterified to other esters of Formula I or converted to the acid or a physiologically acceptable salt by standard methods.In preparing the 5-isoxazolecarboxylates, the appropriately X substituted aldehydes are prepared by conventional substitution methods. Depending upon the substituent itself, the placement of the aldehyde group, the substitution of the pyridine ring can occur on pyridine itself, pyridine aldehyde, or the pyridine dialdehyde, depending upon the orientation direction effect of the substituent. The appropriately substituted starting material is then reacted with an acid addition salt of hydroxylamine under standard conditions to form the pyridine dioxime. The dioxime is then reacted with a halogen gas, preferably chlorine in an organic solvent inert to the gas of a low temperature to form the .alpha.,.alpha.-dihalopyridyldioxime. Halogenated solvents such as carbon tetrachloride, chloroform and methylene chloride are suitable solvents for the halogenation step. The temperature of the reaction should be maintained from 0.degree. to about 30.degree. C., preferably from 0 to about 15.degree. C. The .alpha.,.alpha.-dihalogenated dioxime is then reacted with an alkyl propiolate, alkyl having one to six carbon atoms, inclusive, in an organic solvent and an amine to form the 5-isoxazolecarboxylate. Suitable organic solvents are lower alcohols such as methanol, ethanol, propanol and the like, and cyclic ethers such as tetrahydrofuran and 1,4-dioxane. Suitable amines functioning as an acid scavenging agent are triethylamine, tripropylamine, and higher trialkylamines, 1-methylpiperidine, 1-methylpyrrolidine, 1,4-dimethylpiperazine and the like.The diesters are then converted to the diacids by alkaline hydrolysis with a base such as sodium hydroxide followed by treatment with an acid such as hydrochloric acid. The acid is then readily converted into any of the physiologically acceptable metal or amine salts.Following are illustrative examples of compounds of the invention which can be prepared by the known procedures. TABLE I ______________________________________ ##STR4## R is C.sub.2 H.sub.5 ##STR5## ______________________________________ 4-CH.sub.3 3-i-C.sub.6 H.sub.13 4-t-C.sub.4 H.sub.9 3-OC.sub.2 H.sub.5 3-OC.sub.5 H.sub.11 4-O-i-C.sub.3 H.sub.7 3-OC.sub.2 H.sub.5 4-C.sub.6 H.sub.5 3-C.sub.6 H.sub.5 4-CN 3-NO.sub.2 4-NO.sub.2 3-CF.sub.3 4-CF.sub.3 3-F 4-F 3-Cl 4-Cl 3-Br 4-Br ______________________________________ TABLE IIThe compounds of Table I are converted to esters wherein R is alkyl of one to eight carbon atoms, inclusive, other than ethyl. Examples of such esters are methyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and isomers thereof.TABLE IIIThe compounds of Table I are converted to the diacids by standard methods.TABLE IVThe compounds of Table III are converted to physiologically acceptable salts of the acid, preferably sodium, potassium and tris(hydroxymethyl)aminomethane.Table II, III and IV are not rendered in the same manner as Table I for the purpose of brevity. However, the same scoping is intended.

    摘要翻译： 新颖的式（VI）化合物，其中X是氢，1-6个碳原子的烷基，包括1至6个原子的烷氧基，包括苯基，氰基，硝基，三氟甲基，氟，氯或溴; R是氢，1-8个碳原子的烷基和生理上可接受的金属或胺阳离子和其中R是氢或生理上可接受的金属或胺阳离子的新组合物用于预防性治疗过敏性疾病如哮喘。

    Benzothiazole derivatives
    9.
    发明授权
    Benzothiazole derivatives 失效
    苯并噻唑衍生物

    公开(公告)号：US4423223A

    公开(公告)日：1983-12-27

    申请号：US155712

    申请日：1980-06-02

    申请人： Charles M. Hall ,  John B. Wright

    发明人： Charles M. Hall ,  John B. Wright

    IPC分类号： C07D277/82 ,  C07D277/62

    CPC分类号： C07D277/82

    摘要： Novel compounds of the formula ##STR1## wherein X and Y are the same or different and are hydrogen, fluora, chloro, bromo, alkyl of one to six carbon atoms, inclusive, alkoxy of one to six carbon atoms, inclusive, nitro, cyano, amino, trifluoromethyl, ##STR2## wherein R.sub.1 is alkyl of one to six carbon atoms, inclusive, ##STR3## wherein R.sub.2 and R.sub.3 are the same or different and are hydrogen or alkyl of one to three carbon atoms inclusive, or CO.sub.2 Q where Q is alkyl of one to six carbon atoms, inclusive, hydrogen or a physiologically acceptable metal or amine cation; and R is hydrogen, alkyl of one to eight carbon atoms, inclusive, --CH.sub.2).sub.m phenyl wherein m is 0, 1 or 2 or (CH.sub.2).sub.n NR.sub.4 R.sub.5 wherein n is 1 or 2, and R.sub.4 and R.sub.5 are the same or different and are alkyl of one to three carbon atoms, inclusive, and a physiologically acceptable metal or amine cation; and physiologically acceptable acid addition salts thereof are formulated into pharmaceutical compositions suitable for oral, parenteral or inhalation administration which are used as prophylactic inhibitors of allergic manifestations in sensitized mammals.

    摘要翻译： 新颖的式（Ⅰ）化合物，其中X和Y相同或不同，为氢，氟，氯，溴，含1-6个碳原子的烷基，包括1至6个碳原子的烷氧基，包括硝基，氰基 ，其中R 1为1至6个碳原子的烷基，其中R 2和R 3相同或不同，为氢或含1至3个碳原子的烷基或CO 2 Q，其中Q 是1-6个碳原子的烷基（包括端值），氢或生理上可接受的金属或胺阳离子; 且R为氢，一至八个碳原子的烷基，包括端基的-CH 2）m苯基，其中m为0,1或2或（CH 2）n NR 4 R 5，其中n为1或2，并且R 4和R 5相同或不同， 是一至三个碳原子的烷基，包括端基和生理上可接受的金属或胺阳离子; 并将其生理上可接受的酸加成盐配制成适用于口服，肠胃外或吸入给药的药物组合物，其用作敏化哺乳动物过敏表现的预防性抑制剂。

    DI-Tham salt of 10-cl,1,4,6,9 tetrahydro-5-methyl 4,6 dioxopyrido[3,2-g]quinoline-2,8-dicarboxylate
    10.
    发明授权
    DI-Tham salt of 10-cl,1,4,6,9 tetrahydro-5-methyl 4,6 dioxopyrido[3,2-g]quinoline-2,8-dicarboxylate 失效
    10-CL的DI-THAM盐，1,4,6,9四氢-5-甲基-4,6-二氧代吡啶（3,2-G）喹啉-2,8-二羧酸酯

    公开(公告)号：US4126617A

    公开(公告)日：1978-11-21

    申请号：US712124

    申请日：1976-08-05

    申请人： Charles M. Hall ,  Herbert G. Johnson ,  John B. Wright

    发明人： Charles M. Hall ,  Herbert G. Johnson ,  John B. Wright

    IPC分类号： C07C205/37 ,  C07C205/57 ,  C07D471/04 ,  C07D487/04

    CPC分类号： C07D471/04 ,  C07C205/37 ,  C07C205/57

    摘要： Novel chemical compounds of the formula: ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, phenyl, alkali metal, or an amine cation;X and Y can be the same or different and are selected from the group consisting of hydrogen, alkyl or from one to six carbon atoms, inclusive, cycloalkyl of 5 or 6 carbon atoms, inclusive, phenyl, hydroxyl, alkoxy having from one to three carbon atoms, inclusive, halogen, trifluoromethyl, cyano, carboxyamide and ##STR2## where Q is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, alkali metal, and an amine cation, with the proviso that whereR is hydrogen, alkali metal or an amine cation, then Q is the same as R, and whereR is phenyl or alkyl from one to three carbon atoms, then Q is phenyl or alkyl from one to three carbon atoms; andZ is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, and phenyl.The compounds are formulated with pharmaceutical carriers for oral or parenteral administration, with insufflation being the preferred method. The compositions are useful in the prophylactic treatment of sensitized humans and mammals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature.